Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | FASN | P49327 | 6/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564627 | 0.84 | FASN (0.74) | MAPTKDM4EFASN | |
| SCHEMBL5330425 | 0.84 | KDM4E (0.70) | MAPTKDM4EFASN | |
| SCHEMBL8783774 | 0.82 | FASN (0.74) | MAPTKDM4EFASNCYP1A2POLB | |
| SCHEMBL12686410 | 0.80 | FASN (0.67) | MAPTKDM4EFASNCYP1A2POLB | |
| SCHEMBL4455323 | 0.79 | MAPT (1.00) | MAPTKDM4EFASN | |
| SCHEMBL8783594 | 0.78 | MAPT (0.68) | MAPTKDM4EFASNCYP1A2POLB | |
| SCHEMBL1612505 | 0.78 | KDM4E (0.79) | MAPTKDM4ECYP1A2POLBCYP3A4 | |
| SCHEMBL15648185 | 0.78 | KDM4E (0.70) | MAPTKDM4EFASNTSHR | |
| SCHEMBL14449851 | 0.78 | KDM4E (0.70) | MAPTKDM4EFASN | |
| SCHEMBL8785220 | 0.77 | MAPT (0.62) | MAPTKDM4EFASNCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1981341-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | Merck and Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089634-A2 | INHIBITORS OF FATTY ACID SYNTHASE (FAS) | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048276-A1 | Inhibitors of Fatty Acid Synthase (Fas) | FASN, FADS2, FADS1 | MAPT 4736/4885KDM4E 1768/4885FASN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.